Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

GlobeNewswire September 29, 2022

Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

GlobeNewswire September 21, 2022

Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

GlobeNewswire September 14, 2022

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer's Disease Agitation

GlobeNewswire September 8, 2022

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

GlobeNewswire September 7, 2022

Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire September 6, 2022

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

GlobeNewswire September 1, 2022

AXSOME THERAPEUTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM

Business Wire August 26, 2022

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

GlobeNewswire August 19, 2022

AXSOME THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM

PR Newswire August 12, 2022

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 9, 2022

AXSOME THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM

Business Wire July 30, 2022

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

GlobeNewswire July 28, 2022

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile July 12, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

PR Newswire July 12, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Business Wire July 12, 2022

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders

PR Newswire July 12, 2022

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

PR Newswire July 11, 2022

AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Newsfile July 11, 2022

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)

Business Wire July 11, 2022